All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
On 15th January 2018, the U.S. Food and Drug Administration (FDA) granted approval to arsenic trioxide [ATO] injection in combination with tretinoin for the treatment of adult patients with newly diagnosed low-risk Acute Promyelocytic Leukemia (APL) characterized by the presence of t(15;17) translocation or PML/RAR-alpha gene expression.
This approval for arsenic trioxide was based on the Priority Review granted by the FDA in September 2017, which was based on data from published scientific literature and a review of Teva’s (drug manufacturer) global safety database for ATO.
Arsenic trioxide had been previously approved by the FDA and is indicated for induction of remission and consolidation in patients with APL with t(15;17) translocation or PML/RAR-alpha gene expression who are refractory to or relapsed after retinoid and anthracycline chemotherapy. This label expansion for arsenic trioxide by the FDA to include newly diagnosed APL “represents an important benefit” for patients according to the drug manufacturers.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox